Targeting transcription factors is complicated, and there is still no drug to target MYB[8]; hence, it is necessary to identify applicable targets for ACC treatment by understanding the mechanism of tumorigenesis. The gene discussed is MYB; the disease is adrenal cortex carcinoma.